... Resulta que la información que se dio al salir al mercado no se ajustaba a la realidad, y eso lo sabían, tanto el Gobierno, como el Banco de España. También lo sabía el entonces presidente de la entidad, que ha resultado ser un bluf.
No se trata pues de crédulos clientes, a los que se pueda echar por la borda, aunque no se descarta que lo hagan. Si lo hizo Jordí Pujol con los de Banca Catalana, sin que perdiera ni un ápice de crédito, ¿por qué no lo puede hacer el gobierno de Rajoy? .
En realidad, se trata de contribuyentes que confiaron en las instituciones españolas y sin los cuales el descalabro de Bankia hubiera sido mayor. No es nada correcta la propuesta de que se haga pagar a quienes ninguna culpa tienen del desaguisado llevado a cabo por otros.
...
17 agosto 2012
Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer .
Clin Cancer Res. 2012 Aug 15.
Copyright © 2012, American Association for Cancer Research.
PM01183 , Actualmente Terminando ya la Fase II en Ovario ...
Cáncer de Ovario Epitelial, Encontar una Nueva Terapia que Supere la Resistencia a los Platinos es una Prioridad .(Hospital Universitari de Bellvitge) ...
Aqui tenemos unos Resultados ( Mayo 2012 ) de Fases Anteriores en Cancer de Ovario de este Farmaco de Pharma Mar ( G. Zeltia ) publicadas esta semana en la Publicación : Clinical Cancer Research de la American Association for Cancer Research :
Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer.
Source Pathology, Hospital Universitari de Bellvitge.
Vidal A, Munoz C, Guillen MJ, Moreto J, Sara P, Martinez-Iniesta M, Figueras A, Padulles L, Garcia-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Marti L, Ponce J, Mollevi DG, Capella G, Condom E, Vinals F, Huertas D, Cuevas C, Esteller M, Aviles P, Villanueva A.
Abstract
PURPOSE: Epithelial ovarian cancer (EOC) is the fifth leading cause of death in women diagnosed with gynecological malignancies. The low survival rate is due to its advanced-stage diagnosis and either intrinsic or acquired resistance to standard platinum-based chemotherapy. So, the development of effective innovative therapeutic strategies to overcome cisplatin resistance remains a high priority.
EXPERIMENTAL DESIGN: To investigate new treatments in in vivo models reproducing EOCs tumor growth, we generated a preclinical model of ovarian cancer after orthotopic implantation of a primary serous tumor in nude mice. Further, matched model of acquired cisplatin-resistant tumor version was successfully derived in mice. Effectiveness of lurbinectedin (PM01183) treatment, a novel marine-derived DNA minor groove covalent binder, was assessed in both preclinical models as a single and a combined-cisplatin agent.
RESULTS: Orthotopically perpetuated tumor grafts mimic the histopathological characteristics of primary patients' tumors and they also recapitulate in mice characteristic features of tumor response to cisplatin treatments. We demonstrated that single lurbinectedin or cisplatin combined therapies were effective in treating cisplatin-sensitive and cisplatin-resistant preclinical ovarian tumor models. Furthermore, the strongest in vivo synergistic effect was observed for combined treatments, especially in cisplatin-resistant tumors. Lurbinectedin tumor growth inhibition was associated with reduced proliferation, increased rate of aberrant mitosis and subsequent induced apoptosis.
CONCLUSIONS: Taken together, preclinical orthotopic ovarian tumor grafts are useful tools for drug development, providing hard evidence that lurbinectedin might be a useful therapy in the treatment of epithelial ovarian cancer by overcoming cisplatin resistance.
...
Copyright © 2012, American Association for Cancer Research.
PM01183 , Actualmente Terminando ya la Fase II en Ovario ... Cáncer de Ovario Epitelial, Encontar una Nueva Terapia que Supere la Resistencia a los Platinos es una Prioridad .(Hospital Universitari de Bellvitge) ...
Aqui tenemos unos Resultados ( Mayo 2012 ) de Fases Anteriores en Cancer de Ovario de este Farmaco de Pharma Mar ( G. Zeltia ) publicadas esta semana en la Publicación : Clinical Cancer Research de la American Association for Cancer Research :
Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer.
Source Pathology, Hospital Universitari de Bellvitge.
Vidal A, Munoz C, Guillen MJ, Moreto J, Sara P, Martinez-Iniesta M, Figueras A, Padulles L, Garcia-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Marti L, Ponce J, Mollevi DG, Capella G, Condom E, Vinals F, Huertas D, Cuevas C, Esteller M, Aviles P, Villanueva A.
Abstract
PURPOSE: Epithelial ovarian cancer (EOC) is the fifth leading cause of death in women diagnosed with gynecological malignancies. The low survival rate is due to its advanced-stage diagnosis and either intrinsic or acquired resistance to standard platinum-based chemotherapy. So, the development of effective innovative therapeutic strategies to overcome cisplatin resistance remains a high priority.
EXPERIMENTAL DESIGN: To investigate new treatments in in vivo models reproducing EOCs tumor growth, we generated a preclinical model of ovarian cancer after orthotopic implantation of a primary serous tumor in nude mice. Further, matched model of acquired cisplatin-resistant tumor version was successfully derived in mice. Effectiveness of lurbinectedin (PM01183) treatment, a novel marine-derived DNA minor groove covalent binder, was assessed in both preclinical models as a single and a combined-cisplatin agent.
RESULTS: Orthotopically perpetuated tumor grafts mimic the histopathological characteristics of primary patients' tumors and they also recapitulate in mice characteristic features of tumor response to cisplatin treatments. We demonstrated that single lurbinectedin or cisplatin combined therapies were effective in treating cisplatin-sensitive and cisplatin-resistant preclinical ovarian tumor models. Furthermore, the strongest in vivo synergistic effect was observed for combined treatments, especially in cisplatin-resistant tumors. Lurbinectedin tumor growth inhibition was associated with reduced proliferation, increased rate of aberrant mitosis and subsequent induced apoptosis.
CONCLUSIONS: Taken together, preclinical orthotopic ovarian tumor grafts are useful tools for drug development, providing hard evidence that lurbinectedin might be a useful therapy in the treatment of epithelial ovarian cancer by overcoming cisplatin resistance.
...